USANA Health Sciences (USNA) Tops Q3 EPS by 27c; Trims Outlook

USANA Health Sciences (NYSE: USNA) reported Q3 EPS of $2.40, $0.27 better than the analyst estimate of $2.13. Revenue for the quarter came in at $254.2 million versus the consensus estimate of $263.37 million.

GUIDANCE:

USANA Health Sciences sees FY2016 EPS of $7.90-$8.10, versus prior guidance of $7.90-$8.20 and the consensus of $8.10. USANA Health Sciences sees FY2016 revenue of $1.00-1.01 billion, versus the consensus of $1.03 billion.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• BofA lists top 5 themes driving next $1tn in incremental semi sales